公开(公告)号：US20220220157A1

公开(公告)日：2022-07-14

申请号：US17583511

申请日：2022-01-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Riccardo CORTESE ,  Fabiana GRAZIOLI ,  Alfredo NICOSIA ,  Alessandra VITELLI

IPC: C07K14/005 ,  C12N15/86 ,  C07K14/075 ,  C07K14/75 ,  A61K39/12 ,  C12N15/861 ,  A61K39/155 ,  A61K39/21 ,  C12N7/00

Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

公开(公告)号：US20220112245A2

公开(公告)日：2022-04-14

申请号：US16467569

申请日：2017-12-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: C07K14/005 ,  A61K39/39 ,  A61K39/205 ,  C12N15/86 ,  A61P31/14 ,  A61K39/21 ,  A61P31/18 ,  A61K39/12

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US20220275397A1

公开(公告)日：2022-09-01

申请号：US17742221

申请日：2022-05-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefania CAPONE ,  Stefano COLLOCA ,  Antonella FOLGORI ,  Rossella MERONE

IPC: C12N15/86 ,  A61K39/21 ,  C07K14/005 ,  A61K39/12 ,  A61P31/18 ,  A61P31/14

Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

公开(公告)号：US20220204566A1

公开(公告)日：2022-06-30

申请号：US17565796

申请日：2021-12-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano COLLOCA ,  Virginia AMMENDOLA ,  Fabiana GRAZIOLI ,  Alessandra Franz VITELLI ,  Alfredo NICOSIA ,  Riccardo CORTESE

IPC: C07K14/005 ,  C12N15/86 ,  C07K14/075 ,  C07K14/75 ,  A61K39/12 ,  C12N15/861 ,  A61K39/155 ,  A61K39/21 ,  C12N7/00

Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

公开(公告)号：US20230158134A1

公开(公告)日：2023-05-25

申请号：US18075064

申请日：2022-12-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00 ,  A61P31/14

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US20210246468A1

公开(公告)日：2021-08-12

申请号：US16973630

申请日：2019-06-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefania CAPONE ,  Stefano COLLOCA ,  Antonella FOLGORI ,  Rosella MERONE

IPC: C12N15/86 ,  A61K39/21 ,  A61P37/04

Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

公开(公告)号：US20210069322A1

公开(公告)日：2021-03-11

申请号：US16772203

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  C12N15/86 ,  C07K14/02 ,  A61P31/20

Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

公开(公告)号：US20210060150A1

公开(公告)日：2021-03-04

申请号：US16986413

申请日：2020-08-06

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano COLLOCA ,  Virginia AMMENDOLA ,  Fabiana GRAZIOLI ,  Alessandra VITELLI ,  Alfredo NICOSIA ,  Riccardo CORTESE

IPC: A61K39/04 ,  C12N15/86 ,  A61K39/12 ,  C12N7/00 ,  A61P31/06 ,  A61K35/761 ,  C07K14/005 ,  C07K14/35 ,  A61K9/00 ,  A61K39/39 ,  A61K45/00 ,  C12N15/85

Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

公开(公告)号：US20240382583A1

公开(公告)日：2024-11-21

申请号：US18609504

申请日：2024-03-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

公开(公告)号：US20210189421A1

公开(公告)日：2021-06-24

申请号：US16756376

申请日：2018-10-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI

IPC: C12N15/86 ,  C12N7/00 ,  A61K9/00 ,  A61K39/12

Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.